Lung Cancer Patient given Chemotherapy through In Vivo Lung Perfusion with STEEN Solution™

A leading hospital enrolled their first patient into a clinical trial to provide chemotherapy to patients suffering from lung sarcomas.  According to the 2016 data from the American Cancer Society, soft tissue sarcomas affect approximately 12,310 people annually in the United States and more than 4,990 Americans will die each year of this disease.  Of the patients who develop extremity sarcoma, approximately 20% will have isolated pulmonary metastatic disease at some point in the course of their disease.  Surgery is the preferred way of treating pulmonary sarcomas but due to micrometastasis, that cannot be seen, the person has a greater than 70% risk of pulmonary recurrence after this surgery. The use of systemic chemotherapy has not been used due to the significant side effects with unproven benefit. With the use of in-vivo lung perfusion the surgeon can shut off the lung from the systemic circulation and give the chemotherapy only to the lung so as not to affect the rest of the body.

“This is a significant step forward in expanding the capability of IVLP in cancer therapy.  The dosage of chemotherapy given is yet to be determined to give optimal therapy with reduced side effects but this is the beginning of a new chapter in cancer therapy”, says Magnus Nilsson, CEO of XVIVO Perfusion.

June 22, 2016
Gothenburg
XVIVO Perfusion AB (publ)